Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

lintuzumab

Phase 3Monoclonal antibody

lintuzumab is one of 168 biologic programs targeting Leukemia. It is currently in Phase 3.

5

Indications

11

Total Trials

0

Active Trials

167

Competitors

Pipeline

Status by Indication[3][1]

Indication

LeukemiaActive, not recruiting

Chronic Myelogenous LeukemiaActive, not recruiting

Acute Promyelocytic LeukemiaActive, not recruiting

Myelodysplastic SyndromeActive, not recruiting

Myelodysplastic SyndromesActive, not recruiting

LeukemiaPhase 3

Active, not recruiting

Chronic Myelogenous LeukemiaPhase 2

Active, not recruiting

Acute Promyelocytic LeukemiaPhase 2

Active, not recruiting

Myelodysplastic SyndromePhase 1

Active, not recruiting

Myelodysplastic SyndromesPhase 2

Active, not recruiting

Competition

Competitive Landscape

508 competitors in Leukemia

#DrugCompanyPhaseTrials

Cytosar

Trexall

Alnylam Pharmaceuticals

Rituxan

Oncovin

Vepesid

Decadron

AAspen Global Incorporated

Leukine

Oncovin

EEastern Cooperative Oncology Group

Rayos

RRoxane Laboratories

Busulfex

Akero Therapeutics

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Myelogenous Leukemia2 trials

Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00002800·60 enrolled

Monoclonal Antibody Therapy in Treating Patients With Myelodysplastic Syndrome or Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelogenous Leukemia

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00002890·24 enrolled

Leukemia2 trials

Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia

Unknown status·JJonsson Comprehensive Cancer Center·Phase 2·NCT00006084

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia

Unknown status·FFacet Biotech·Phase 3·NCT00006045

Myelodysplastic Syndromes2 trials

Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes

Terminated·AAlison Walker·Phase 2·NCT00997243·7 enrolled

A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)

Completed· Pfizer logo

Pfizer·Phase 1·NCT00502112·13 enrolled

Acute Promyelocytic Leukemia2 trials

Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00016159·35 enrolled

Monoclonal Antibody Therapy and Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia in Remission

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00002609·40 enrolled

Myelodysplastic Syndrome2 trials

A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

Completed· Pfizer logo

Pfizer·Phase 1·NCT00283114·82 enrolled

Monoclonal Antibody Therapy in Treating Patients With Primary Myelodysplastic Syndrome

Withdrawn·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00003984

1 more indication

AML1 trial

A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML

Completed· Pfizer logo

Pfizer·Phase 2·NCT00528333·211 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for lintuzumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — lintuzumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for lintuzumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: Pfizer

Related News